AMENDMENTS TO THE CLAIMS

Please replace the currently pending claims with the following listing of claims:

1-42. **(Canceled)**

43. **(Canceled)** ~~A method of inhibiting proliferation of tumor cells in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that binds to Cripto and a pharmaceutically acceptable carrier~~.

2 ~~44.~~ **(Currently amended)** The method according to claim 1 ~~46 43~~, wherein the subject is human.

45. **(Canceled)** ~~A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that binds to Cripto and a pharmaceutically acceptable carrier in an effective amount.~~

1 ~~46.~~ **(Previously presented)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from about amino acid 46 to about amino acid 62 of SEQ ID NO:1 or SEQ ID NO:2 in an effective amount. amino acid residues from about amino acid 46 to about amino acid 62 of

3 ~~47.~~ **(Previously presented)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the cysteine-rich domain of Cripto spanning from about amino acid residue 114 to about amino acid residue 150 of SEQ ID No:1 or SEQ ID NO:2 in an effective amount. from about amino acid residue 114 to about amino acid residue 150 of

4 ~~48.~~ **(Currently amended)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody which binds specifically to an epitope of Cripto selected from the group of epitopes to which antibodies produced by hybridomas A6C12.11, A6F8.6, ~~A7H1.19, A8F1.30,~~ A8G3.5, A19A10.30, A10B2.18, ~~A2D3.23, A7A10.29, A9G9.9, A15C12.10, A15E4.14,~~ A17A2.16, ~~A17C12.28, A17G12.1, A17H6.1, A18B3.11,~~ and B3F6.17~~, and B11H8.4~~ bind in an effective amount.

49. **(Canceled)**

5 ~~50.~~ **(Currently amended)** The method according to claim ~~46~~ 1 ~~43~~, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

51-58. **(Canceled)**

6 ~~59.~~ **(Currently amended)** The method of claim ~~46~~ 1 ~~43~~, wherein the antibody is a humanized antibody.

7 ~~60.~~ **(Currently amended)** The method of claim ~~46~~ 1 ~~43~~, wherein the antibody is a human antibody.

61. **Canceled.**

8 ~~62.~~ **(Currently amended)** ~~The~~ A method of ~~claim 43~~ inhibiting proliferation of tumor cells that express Cripto in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that~~, wherein the antibody~~ specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from about amino acid 46 to about amino acid 62 of SEQ ID NO:1 or SEQ ID NO:2 from about amino acid residue 46 to about amino acid residue 62 of and a pharmaceutically acceptable carrier.

9 ~~63.~~ **(Currently amended)** The method of claim 1 ~~46 43~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

10 ~~64.~~ **(Currently amended)** The method of claim 1 ~~46 43~~, wherein the antibody is a full length antibody.

11 ~~65.~~ **(Currently amended)** The method of claim 1 ~~46 43~~, wherein the antibody is a single chain antibody.

12 ~~66.~~ **(Currently amended)** The method of claim 1 ~~46 43~~, wherein the antibody is conjugated to a chemotherapeutic agent.

13 ~~67.~~ **(Currently amended)** The method of claim 1 ~~46 43~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

14 ~~68.~~ **(Currently amended)** The method of claim 12 ~~66~~, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

15 ~~69.~~ **(Currently amended)** The ~~antibody~~ method of claim 14 ~~68~~, wherein the agent is a maytansinoid.

16 ~~70.~~ **(Currently amended)** ~~The~~ A method of ~~claim 43,~~ inhibiting proliferation of tumor cells that express cripto in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal ~~wherein the~~ antibody that specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from about amino acid 46-62 of SEQ ID NO:1 or 2, wherein the amino acid residues from about amino acid 46-62 of SEQ ID NO: ~~which~~ antibody ~~or fragment~~ is conjugated to a maytansinoid, and a pharmaceutically acceptable carrier.

17 ~~71.~~ **(Currently amended)** ~~The~~ A method of ~~claim 43~~ inhibiting proliferation of tumor cells that express cripto in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that binds to Cripto, wherein the antibody is a humanized version of the antibody produced by the hybridoma B3F6.17.

18 ~~72.~~ **(Currently amended)** ~~The~~ A method of ~~claim 43~~ inhibiting proliferation of tumor cells that express cripto in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal~~, wherein the~~ antibody that specifically binds to an epitope of Cripto ~~selected from the group of epitopes~~ to which an antibody ~~antibodies~~ produced by hybridoma ~~hybridomas selected from the group consisting of A10B2.18 and~~ B3F6.17 binds, and a pharmaceutically acceptable carrier.

19 ~~73.~~ **(Currently amended)** ~~The~~ A method of ~~claim 43~~ inhibiting proliferation of tumor cells that express Cripto in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody~~, that, wherein~~ ~~the antibody specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO:2~~ and ~~which~~ is capable of internalizing Cripto.

wherein the antibody specifically binds to an epitope of Cripto selected from the group of epitopes to which antibodies produced by hybridomas of A2.7F6.1 and B3F6.17 bind,

20 ~~74.~~ **(Currently amended)** ~~The~~ A method of ~~claim 43~~ inhibiting proliferation of tumor cells that express cripto in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal~~, wherein the~~ antibody that specifically binds to an epitope of Cripto comprised in the cysteine-rich domain of Cripto spanning from about amino acid residue 114 to about amino acid residue 150 of SEQ ID NO:1 or SEQ ID NO:2, and a pharmaceutically acceptable carrier.

from about amino acid residue 114 to about amino acid residue 150 of

21 ~~75.~~ **(Currently amended)** ~~The~~ A method of ~~claim 43~~ inhibiting proliferation of tumor cells that express Cripto in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that binds to Cripto, wherein the antibody specifically binds to an epitope of Cripto selected from the group of epitopes to which antibodies produced by hybridomas ~~selected from the group consisting of~~ A6.C12.11, A8G3.5, and A6F8.6 bind, and a pharmaceutically acceptable carrier.

22 ~~76.~~ **(Currently amended)** ~~The~~ A method of ~~claim 43~~ inhibiting proliferation of tumor cells that express Cripto in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that~~, wherein the antibody~~ specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO:2 ~~which~~ and inhibits the interaction of Cripto and ALK4.

23 77. **(Currently amended)** ~~The~~ A method of ~~claim 43~~ inhibiting proliferation of tumor cells that express cripto in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal~~, wherein the~~ antibody that binds specifically to an epitope of Cripto selected from the group of epitopes to which antibodies produced by hybridomas A6C12.11, A6F8.6, ~~A7H1.19, A8F1.30,~~ A8G3.5, A19A10.30, A10B2.18, ~~A2D3.23, A7A10.29, A9G9.9, A15C12.10, A15E4.14,~~ A17A2.16, ~~A17C12.28, A17G12.1, A17H6.1, A18B3.11,~~ and B3F6.17~~, and B11H8.4~~ bind, and a pharmaceutically acceptable carrier.

78. **(Canceled)** ~~The method of claim 43, wherein the antibody binds to an epitope comprised in the extracellular domain spanning amino acid residues 31-188 of SEQ ID NO:1 or SEQ ID NO:2.~~

79. **(Canceled)** ~~The method of claim 43, wherein the antibody binds to an epitope comprised in the ligand-receptor binding domain spanning amino acid residues 75-150 of SEQ ID NO:1 or SEQ ID NO:2.~~

80. **(Canceled)** ~~The method of claim 43, wherein the antibody binds to an epitope comprised in the EGF-like domain spanning amino acid residues 75-112 of SEQ ID NO:1 or SEQ ID NO:2.~~

24 ~~81.~~ **(New)** A method of inhibiting proliferation of tumor cells that express Cripto in a subject comprising the step of administering to the subject an effective amount of a composition comprising a monoclonal antibody that binds to Cripto, wherein the antibody specifically binds to an epitope of Critpo to which an antibody produced by hybridoma A10B2.18 binds, and a pharmaceutically acceptable carrier.

25 ~~82.~~ **(New)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto comprised in the domain spanning amino acid residues from about amino acid 46-62 of SEQ ID NO:1 or 2, wherein the antibody is conjugated to a maytansinoid, in an effective amount.

amino acid residues from about amino acid 46-62 of SEQ ID NO:

26 ~~83.~~ **(New)** A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a humanized version of the antibody produced by the hybridoma B3F6.17 in an effective amount.

27 ~~84.~~ (New) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto to which an antibody produced by the hybridoma B3F6.17 binds in an effective amount.

28 ~~85.~~ (New) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto to which an antibody produced by the hybridoma A10B2.18 binds in an effective amount.

29 ~~86.~~ (New) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody wherein the antibody specifically binds to an epitope of Cripto selected from the group of epitopes to which antibodies produced by hybridomas of A27F6.1 and B3F6.17 bind ~~that specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2~~ and is capable of internalizing Cripto in an effective amount.

30 ~~87.~~ (New) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to an epitope of Cripto selected from the group of epitopes to which antibodies produced by hybridomas A6.C12.11, A8G3.5, and A6F8.6 bind in an effective amount.

31 ~~88.~~ (New) A method of treating a subject having a tumor that over-expresses Cripto comprising administering to the subject a composition comprising a monoclonal antibody that specifically binds to a Cripto amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 and inhibits the interaction of Cripto and ALK4 in an effective amount.

32 ~~89.~~ (New) The method according to claim 3 ~~47~~, wherein the subject is human.

33 ~~90.~~ (New) The method according to claim 3 ~~47~~, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

34 ~~91~~. (New) The method of claim ~~47~~ 3, wherein the antibody is a humanized antibody.

35 ~~92~~. (New) The method of claim ~~47~~ 3, wherein the antibody is a human antibody.

36 ~~93~~. (New) The method of claim ~~47~~ 3, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

37 ~~94~~. (New) The method of claim ~~47~~ 3, wherein the antibody is a full length antibody.

38 ~~95~~. (New) The method of claim ~~47~~ 3, wherein the antibody is a single chain antibody.

39 ~~96~~. (New) The method of claim ~~47~~ 3, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

40 ~~97~~. (New) The method of claim ~~47~~ 3, wherein the antibody is conjugated to a chemotherapeutic agent.

41 ~~98~~. (New) The method of claim ~~97~~ 40, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

42 ~~99~~. (New) The antibody of claim ~~98~~ 41, wherein the agent is a maytansinoid.

43 ~~100~~. (New) The method according to claim ~~48~~ 4, wherein the subject is human.

44 ~~101~~. (New) The method according to claim ~~48~~ 4, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

45 ~~102~~. (New) The method of claim ~~48~~ 4, wherein the antibody is a humanized antibody.

46 ~~103~~. (New) The method of claim ~~48~~ 4, wherein the antibody is a human antibody.

47 ~~104~~. (New) The method of claim ~~48~~ 4, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

48 ~~105~~. (New) The method of claim ~~48~~ 4, wherein the antibody is a full length antibody.

49 ~~106~~. (New) The method of claim ~~48~~ 4, wherein the antibody is a single chain antibody.

50 ~~107~~. (New) The method of claim ~~48~~ 4, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

51 ~~108~~. (New) The method of claim ~~48~~ 4, wherein the antibody is conjugated to a chemotherapeutic agent.

52 ~~109~~. (New) The method of claim ~~108~~ 51, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

53 ~~110~~. (New) The antibody of claim ~~109~~ 52, wherein the agent is a maytansinoid.

54 ~~111~~. (New) The method according to claim ~~62~~ 8, wherein the subject is human.

55 ~~112~~. (New) The method according to claim ~~62~~ 8, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

56 ~~113~~. (New) The method of claim ~~62~~ 8, wherein the antibody is a humanized antibody.

57 ~~114~~. (New) The method of claim ~~62~~ 8, wherein the antibody is a human antibody.

58 ~~115~~. (New) The method of claim ~~62~~ 8, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

59 ~~116~~. (New) The method of claim ~~62~~ 8, wherein the antibody is a full length antibody.

60 ~~117~~. (New) The method of claim ~~62~~ 8, wherein the antibody is a single chain antibody.

61 ~~118~~. (New) The method of claim ~~62~~ 8, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

62 ~~119~~. (New) The method of claim ~~62~~ 8, wherein the antibody is conjugated to a chemotherapeutic agent.

63 ~~120~~. (New) The method of claim ~~119~~ 62, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

64 ~~121~~ (New) The antibody of claim ~~120~~ 63, wherein the agent is a maytansinoid.

65 ~~122~~. (New) The method according to claim ~~70~~ 16, wherein the subject is human.

66 ~~123~~. (New) The method according to claim ~~70~~ 16, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

67 ~~124~~. (New) The method of claim ~~70~~ 16, wherein the antibody is a humanized antibody.

68 ~~125~~. (New) The method of claim ~~70~~ 16, wherein the antibody is a human antibody.

69 ~~126~~. (New) The method of claim ~~70~~ 16, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

70 ~~127~~. (New) The method of claim ~~70~~ 16, wherein the antibody is a full length antibody.

71 ~~128~~. (New) The method of claim ~~70~~ 16, wherein the antibody is a single chain antibody.

72 ~~129~~. (New) The method according to claim ~~71~~ 17, wherein the subject is human.

73 ~~130~~. (New) The method according to claim ~~71~~ 17, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

74 ~~131~~. (New) The method of claim ~~71~~ 17, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

75 ~~132~~. (New) The method of claim ~~71~~ 17, wherein the antibody is a full length antibody.

76 ~~133~~. (New) The method of claim ~~71~~ 17, wherein the antibody is a single chain antibody.

77 ~~134~~. (New) The method of claim ~~71~~ 17, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

78 ~~135~~. (New) The method of claim ~~71~~ 17, wherein the antibody is conjugated to a chemotherapeutic agent.

79 ~~136~~. (New) The method of claim ~~135~~ 78, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

80 ~~137~~. (New) The antibody of claim ~~136~~ 79, wherein the agent is a maytansinoid.

81 ~~138~~. (New) The method according to claim ~~72~~ 18, wherein the subject is human.

82 ~~139~~. (New) The method according to claim ~~72~~ 18, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

83 ~~140~~. (New) The method of claim ~~72~~ 18, wherein the antibody is a humanized antibody.

84 ~~141~~. (New) The method of claim ~~72~~ 18, wherein the antibody is a human antibody.

85 ~~142~~. (New) The method of claim ~~72~~ 18, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

86 ~~143~~. (New) The method of claim ~~72~~ 18, wherein the antibody is a full length antibody.

87 ~~144~~. (New) The method of claim ~~72~~ 18, wherein the antibody is a single chain antibody.

88 ~~145~~. (New) The method of claim ~~72~~ 18, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

89 ~~146~~. (New) The method of claim ~~72~~ 18, wherein the antibody is conjugated to a chemotherapeutic agent.

90 ~~147~~. (New) The method of claim ~~146~~ 89, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

91 ~~148~~. (New) The antibody of claim ~~147~~ 90, wherein the agent is a maytansinoid.

92 ~~149~~. (New) The method according to claim ~~73~~ 19, wherein the subject is human.

93 ~~150~~. (New) The method according to claim ~~73~~ 19, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

94 ~~151~~. (New) The method of claim ~~73~~ 19, wherein the antibody is a humanized antibody.

95 ~~152~~. (New) The method of claim ~~73~~ 19, wherein the antibody is a human antibody.

96 ~~153~~. (New) The method of claim ~~73~~ 19, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

97 ~~154~~. (New) The method of claim ~~73~~ 19, wherein the antibody is a full length antibody.

98 ~~155~~. (New) The method of claim ~~73~~ 19, wherein the antibody is a single chain antibody.

99 ~~156~~. (New) The method of claim ~~73~~ 19, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

100 157. (New) The method of claim 73, wherein the antibody is conjugated to a chemotherapeutic agent.

101 158. (New) The method of claim 157, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

102 159. (New) The antibody of claim 158, wherein the agent is a maytansinoid.

103 160. (New) The method according to claim 74, wherein the subject is human.

104 161. (New) The method according to claim 74, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

105 162. (New) The method of claim 74, wherein the antibody is a humanized antibody.

106 163. (New) The method of claim 74, wherein the antibody is a human antibody.

107 164. (New) The method of claim 74, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

108 165. (New) The method of claim 74, wherein the antibody is a full length antibody.

109 166. (New) The method of claim 74, wherein the antibody is a single chain antibody.

110 167. (New) The method of claim 74, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

111 ~~168~~. (New) The method of claim ~~74~~ 20, wherein the antibody is conjugated to a chemotherapeutic agent.

112 ~~169~~. (New) The method of claim ~~168~~ 111, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

113 ~~170~~. (New) The antibody of claim ~~169~~ 112, wherein the agent is a maytansinoid.

114 ~~171~~. (New) The method according to claim ~~75~~ 21, wherein the subject is human.

115 ~~172~~. (New) The method according to claim ~~75~~ 21, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

116 ~~173~~. (New) The method of claim ~~75~~ 21, wherein the antibody is a humanized antibody.

117 ~~174~~. (New) The method of claim ~~75~~ 21, wherein the antibody is a human antibody.

118 ~~175~~. (New) The method of claim ~~75~~ 21, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

119 ~~176~~. (New) The method of claim ~~75~~ 21, wherein the antibody is a full length antibody.

120 ~~177~~. (New) The method of claim ~~75~~ 21, wherein the antibody is a single chain antibody.

121 ~~178~~. (New) The method of claim ~~75~~ 21, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

122 ~~179~~. (New) The method of claim ~~75~~ 21, wherein the antibody is conjugated to a chemotherapeutic agent.

123 ~~180~~. (New) The method of claim ~~179~~ 122, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

124 ~~181~~. (New) The antibody of claim ~~180~~ 123, wherein the agent is a maytansinoid.

125 ~~182~~. (New) The method according to claim ~~76~~ 22, wherein the subject is human.

126 ~~183~~. (New) The method according to claim ~~76~~ 22, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

127 ~~184~~. (New) The method of claim ~~76~~ 22, wherein the antibody is a humanized antibody.

128 ~~185~~. (New) The method of claim ~~76~~ 22, wherein the antibody is a human antibody.

129 ~~186~~. (New) The method of claim ~~76~~ 22, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

130 ~~187~~. (New) The method of claim ~~76~~ 22, wherein the antibody is a full length antibody.

131 ~~188~~. (New) The method of claim ~~76~~ 22, wherein the antibody is a single chain antibody.

132 ~~189~~. (New) The method of claim ~~76~~ 22, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

133 ~~190~~. (New) The method of claim ~~76~~ 22, wherein the antibody is conjugated to a chemotherapeutic agent.

134 ~~191~~. (New) The method of claim ~~190~~ 133, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

135 ~~192~~. (New) The antibody of claim ~~191~~ 134, wherein the agent is a maytansinoid.

136 ~~193~~. (New) The method according to claim ~~77~~ 23, wherein the subject is human.

137 ~~194~~. (New) The method according to claim ~~77~~ 23, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

138 ~~195~~. (New) The method of claim ~~77~~ 23, wherein the antibody is a humanized antibody.

139 ~~196~~. (New) The method of claim ~~77~~ 23, wherein the antibody is a human antibody.

140 ~~197~~. (New) The method of claim ~~77~~ 23, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

141 ~~198~~. The method of claim ~~77~~ 23, wherein the antibody is a full length antibody.

142 ~~199~~. (New) The method of claim ~~77~~ 23, wherein the antibody is a single chain antibody.

143 ~~200~~. (New) The method of claim ~~77~~ 23, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

144 ~~201~~. (New) The method of claim ~~77~~ 23, wherein the antibody is conjugated to a chemotherapeutic agent.

145 ~~202~~. (New) The method of claim ~~201~~ 144, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

146 ~~203~~. (New) The antibody of claim ~~202~~ 145, wherein the agent is a maytansinoid.

147 ~~204~~. (New) The method according to claim ~~81~~ 24, wherein the subject is human.

148 ~~205~~. (New) The method according to claim ~~81~~ 24, wherein the tumor cell is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumor cells.

149 ~~206~~. (New) The method of claim ~~81~~ 24, wherein the antibody is a humanized antibody.

150 ~~207~~. (New) The method of claim ~~81~~ 24, wherein the antibody is a human antibody.

151 ~~208~~. (New) The method of claim ~~81~~ 24, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

152 ~~209~~. (New) The method of claim ~~81~~ 24, wherein the antibody is a full length antibody.

153 ~~210~~. (New) The method of claim ~~81~~ 24, wherein the antibody is a single chain antibody.

154 ~~211~~. (New) The method of claim ~~81~~ 24, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

155 ~~212~~. (New) The method of claim ~~81~~ 24, wherein the antibody is conjugated to a chemotherapeutic agent.

156 ~~213~~. (New) The method of claim ~~212~~ 155, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

157 ~~214~~. (New) The antibody of claim ~~213~~ 156, wherein the agent is a maytansinoid.

158 ~~215~~. (New) The method according to claim ~~82~~ 25, wherein the subject is human.

159 ~~216~~. (New) The method according to claim ~~82~~ 25, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

160 ~~217~~. (New) The method of claim ~~82~~ 25, wherein the antibody is a humanized antibody.

161 ~~218~~. (New) The method of claim ~~82~~ 25, wherein the antibody is a human antibody.

162 ~~219~~. (New) The method of claim ~~82~~ 25, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

163 ~~220~~. (New) The method of claim ~~82~~ 25, wherein the antibody is a full length antibody.

164 ~~221~~. (New) The method of claim ~~82~~ 25, wherein the antibody is a single chain antibody.

165 ~~222~~. (New) The method according to claim ~~83~~ 26, wherein the subject is human.

166 ~~223~~. (New) The method according to claim ~~83~~ 26, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

167 ~~224~~. (New) The method of claim ~~83~~ 26, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

168 ~~225~~. (New) The method of claim ~~83~~ 26, wherein the antibody is a full length antibody.

169 ~~226~~. (New) The method of claim ~~83~~ 26, wherein the antibody is a single chain antibody.

170 ~~227~~. (New) The method of claim ~~83~~ 26, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

171 ~~228~~. (New) The method of claim ~~83~~ 26, wherein the antibody is conjugated to a chemotherapeutic agent.

172 ~~229~~. (New) The method of claim ~~228~~ 171, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

173 ~~230~~. (New) The antibody of claim ~~229~~ 172, wherein the agent is a maytansinoid.

174 ~~231~~. (New) The method according to claim ~~84~~ 27, wherein the subject is human.

175 ~~232~~. (New) The method according to claim ~~84~~ 27, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

176 ~~233~~. (New) The method of claim ~~84~~ 27, wherein the antibody is a humanized antibody.

177 ~~234~~. (New) The method of claim ~~84~~ 27, wherein the antibody is a human antibody.

178 ~~235~~. (New) The method of claim ~~84~~ 27, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

179 ~~236~~. (New) The method of claim ~~84~~ 27, wherein the antibody is a full length antibody.

180 ~~237~~. (New) The method of claim ~~84~~ 27, wherein the antibody is a single chain antibody.

181 ~~238~~. (New) The method of claim ~~84~~ 27, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

182 ~~239~~. (New) The method of claim ~~84~~ 27, wherein the antibody is conjugated to a chemotherapeutic agent.

183 ~~240~~. (New) The method of claim ~~239~~ 182, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

184 ~~241~~. (New) The antibody of claim ~~240~~ 183, wherein the agent is a maytansinoid.

185 ~~242~~. (New) The method according to claim ~~85~~ 28, wherein the subject is human.

186 ~~243~~. (New) The method according to claim ~~85~~ 28, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

187 ~~244~~. (New) The method of claim ~~85~~ 28, wherein the antibody is a humanized antibody.

188 ~~245~~. (New) The method of claim ~~85~~ 28, wherein the antibody is a human antibody.

189 ~~246~~. (New) The method of claim 28 ~~85~~, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

190 ~~247~~. (New) The method of claim 28 ~~85~~, wherein the antibody is a full length antibody.

191 ~~248~~. (New) The method of claim 28 ~~85~~, wherein the antibody is a single chain antibody.

192 ~~249~~. (New) The method of claim 28 ~~85~~, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

193 ~~250~~. (New) The method of claim 28 ~~85~~, wherein the antibody is conjugated to a chemotherapeutic agent.

194 ~~251~~. (New) The method of claim 193 ~~250~~, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

195 ~~252~~. (New) The antibody of claim 194 ~~251~~, wherein the agent is a maytansinoid.

196 ~~253~~. (New) The method according to claim 29 ~~86~~, wherein the subject is human.

197 ~~254~~. (New) The method according to claim 29 ~~86~~, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

198 ~~255~~. (New) The method of claim 29 ~~86~~, wherein the antibody is a humanized antibody.

199 ~~256~~. (New) The method of claim 29 ~~86~~, wherein the antibody is a human antibody.

200 ~~257~~. (New) The method of claim ~~86~~ 29, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

201 ~~258~~. (New) The method of claim ~~86~~ 29, wherein the antibody is a full length antibody.

202 ~~259~~. (New) The method of claim ~~86~~ 29, wherein the antibody is a single chain antibody.

203 ~~260~~. (New) The method of claim ~~86~~ 29, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

204 ~~261~~. (New) The method of claim ~~86~~ 29, wherein the antibody is conjugated to a chemotherapeutic agent.

205 ~~262~~. (New) The method of claim ~~261~~ 204, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

206 ~~263~~. (New) The antibody of claim ~~262~~ 205, wherein the agent is a maytansinoid.

207 ~~264~~. (New) The method according to claim ~~87~~ 30, wherein the subject is human.

208 ~~265~~. (New) The method according to claim ~~87~~ 30, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

209 ~~266~~. (New) The method of claim ~~87~~ 30, wherein the antibody is a humanized antibody.

210 ~~267~~. (New) The method of claim ~~87~~ 30, wherein the antibody is a human antibody.

241 ~~268~~. (New) The method of claim ~~87~~ 30, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

242 ~~269~~. (New) The method of claim ~~87~~ 30, wherein the antibody is a full length antibody.

243 ~~270~~. (New) The method of claim ~~87~~ 30, wherein the antibody is a single chain antibody.

244 ~~271~~. (New) The method of claim ~~87~~ 30, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

245 ~~272~~. (New) The method of claim ~~87~~ 30, wherein the antibody is conjugated to a chemotherapeutic agent.

246 ~~273~~. (New) The method of claim ~~272~~ 245, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

247 ~~274~~. (New) The antibody of claim ~~273~~ 245, wherein the agent is a maytansinoid.

248 ~~275~~. (New) The method according to claim ~~88~~ 31, wherein the subject is human.

249 ~~276~~. (New) The method according to claim ~~88~~ 31, wherein the tumor is selected from the group consisting of breast, testicular, colon, lung, ovary, bladder, uterine, cervical, pancreatic, and stomach tumors.

250 ~~277~~. (New) The method of claim ~~88~~ 31, wherein the antibody is a humanized antibody.

251 ~~278~~. (New) The method of claim ~~88~~ 31, wherein the antibody is a human antibody.

222 279. (New) The method of claim 31 88, wherein the antibody is an antibody fragment selected from the group consisting of a Fab, a Fab', and a F(ab')2 fragment.

223 280. (New) The method of claim 31 88, wherein the antibody is a full length antibody.

224 281. (New) The method of claim 31 88, wherein the antibody is a single chain antibody.

225 282. (New) The method of claim 31 88, wherein the antibody is administered in combination with a chemotherapeutic agent which is not conjugated to the antibody.

226 283. (New) The method of claim 31 88, wherein the antibody is conjugated to a chemotherapeutic agent.

227 284. (New) The method of claim 226 283, wherein the chemotherapeutic agent is selected from the group consisting of a tumor-activated prodrug, a radionuclide and a toxin.

228 285. (New) The antibody of claim 227 284, wherein the agent is a maytansinoid.